Conference Objectives
- Introduce the different mechanisms of antibiotic resistance in Gram-positive bacteria
- Update on the epidemiology of nosocomial infections due to multi-drug resistant (MDR) Gram-positive bacteria
- Evaluate conventional methods and new techniques for routine and rapid diagnosis of MDR
- Review the most appropriate methods for susceptibility testing, including screening and automatic techniques
- Present state-of-the art management of MDR infections
- Discuss present and future options in the treatment of multiply resistant Gram-positive bacteria
- Critically review the anti-Gram-positive drug pipeline
- Discuss current criteria for prophylaxis and future measures for preventing MDR infections and limiting their spread
Presentations
All presentations are available for ESCMID Members. Please log in or register.
Optimising definitions of risk factors for MDR
Roberto Cauda, Rome, IT
Molecular basis of glycopeptide resistance
Patrice Courvalin, Paris, FR
Molecular basis of resistance to new anti-Gram-positive agents
Roland Leclercq, Caen, FR
VISA definition and actual importance
Robin Howe, Cardiff, UK
Laboratory diagnosis of MDR in hospitals and in the community
Margareta Ieven, Edegem, BE
Role of nasal/oral carriage in spread of MDR
Alex Van Belkum, Leiden, NL
Tracing the MDR spread
Marc Struelens, Brussels, BE
CA-MRSA: Europe vs. USA
Oana Dumitrescu, Lyon, FR
Role and importance of MDR MRSE
Georg Peters, Muenster, DE
Biodiversity and methicillin resistance in staphylococci from the commensal flora
Antoine Andremont, Paris, FR
Presentation not available
National guidelines for MDR control and prevention
Hilary Humphreys, Dublin, IE
VRE in Europe: current problems and extent of risk
Wolfgang Witte, Wernigerode, DE
Schedules and administration routes
Alasdair MacGowan, Bristol, UK
Beta-lactams for MDR GPC?
Javier Garau, Barcelona, Spain
Glycopeptides in today’s clinical practice
Christian Brun-Buisson, Cretail, FR
Fluoroquinolones: state of the art and future needs
Hartmut Lode, Berlin, DE
De facto MDR: difficult treatment of non-MDR strains
Helen Giamarellou, Athens, GR
MDR in VAP/HAP
Jordi Rello, Tarragona, ES
Presentation not available
Inhalation of antibiotics and its effectiveness in MDR-caused VAP
Jean Chastre, Paris, FR
Treating MDR-caused endocarditis
Riccardo Utili, Naples, IT
Current therapy of MRSA invasive disease
Emilio Bouza, Madrid, ES
Skin and soft-tissue infections caused by MDR strains
Winfried Kern, Freiburg, DE
Antibiotic combinations to treat MDR
Matthew Falagas, Athens, GR
Role of decontamination
Evelina Tacconelli, Rome, IT
Any role for statins?
Jonathan Cohen, Brighton, UK
The anti-Gram-positive pipeline: Dalbavancin
Damien Simoneau, Pfizer Europe
Presentation not available
The anti-Gram-positive pipeline: Telavancin
Malcolm Brown, Astellas Pharma Europe
Presentation not available
